

"Express Mail" mailing label number EM348808109 US. I hereby certify that this document and referenced attachments are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR § 1.10, addressed to: Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231 on 1 DEC 98

By: [Signature]
Printed: John C. Cherry

jc523 U.S. PRO
09/203548
12/01/98

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Goli et al.

Title: NOVEL HUMAN CYTOKINE/STEROID RECEPTOR PROTEIN

Serial No.: To Be Assigned

Filing Date:

Herewith

Examiner: To Be Assigned

Group Art Unit:

To Be Assigned

Assistant Commissioner for Patents
Box Patent Application
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants wish to call to the attention of the Examiner the enclosed "List of References Cited by Applicants." The right is reserved to antedate any item in accordance with standard procedure. Copies of references 1 through 21 are not included as these were cited by Applicant or the Examiner in the parent application Serial No. 08/822,264, filed March 20, 1997, and should be available there.

Citation of the documents is not to be construed as an admission that the documents are necessarily prior art with respect to the instant invention. This submission is understood to complement the results of the Examiner's own independent search. Citation of the documents shall not be construed as a representation that a search has been made or that the cited items are inclusive of all the relevant and material citations that may be available publicly. Any NCBI report included herein may not have an accurate date for prior art purposes. Some of the documents may have markings thereon. No significance is meant to be attached to the markings.

Applicants respectfully request that the cited documents be considered by the Examiner

and that an initialed copy of the List of References Cited by Applicants be returned to Applicants.

It is believed that this disclosure complies with 37 CFR §§ 1.56, 1.97 and 1.98 and the Manual of Patent Examining Procedures § 609. If for some reason the Examiner considers otherwise, please telephone the undersigned.


Applicants believe that no fee is due with this paper. However, if the Commissioner determines that a fee is necessary, the Commissioner is hereby authorized to charge any additional fees associated with this communication or credit any overpayment to Incyte Pharmaceuticals, Inc. Deposit Account No. 09-0108. **A duplicate copy of this communication is enclosed.**

If there are any questions regarding the above, the Examiner is invited to call the undersigned at 650-845-4842.

Respectfully submitted,

INCYTE PHARMACEUTICALS, INC.

Date: December 1, 1998



Sheela Mohan-Peterson, Esq.
Reg. No. 41,201

3174 Porter Drive
Palo Alto, California 94304
Phone: (650) 845-4842
Fax: (650) 849-8886

US Patents, its are noted

References cite listed

5,976,837

5,429,948